You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 22, 2025

CLINICAL TRIALS PROFILE FOR ZEMPLAR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Zemplar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00048438 ↗ Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) Completed Abbott Phase 3 2002-02-01 The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
NCT00048451 ↗ Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) Completed Abbott Phase 3 2002-02-01 The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
NCT00048516 ↗ Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing) Completed Abbott Phase 3 2002-02-01 The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zemplar

Condition Name

Condition Name for Zemplar
Intervention Trials
Chronic Kidney Disease 17
Secondary Hyperparathyroidism 17
Hemodialysis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zemplar
Intervention Trials
Kidney Diseases 38
Renal Insufficiency, Chronic 36
Hyperparathyroidism 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zemplar

Trials by Country

Trials by Country for Zemplar
Location Trials
United States 212
Greece 8
Spain 8
Malaysia 7
Poland 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zemplar
Location Trials
California 14
Texas 13
Florida 13
New York 12
Illinois 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zemplar

Clinical Trial Phase

Clinical Trial Phase for Zemplar
Clinical Trial Phase Trials
Phase 4 18
Phase 3 13
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zemplar
Clinical Trial Phase Trials
Completed 48
Terminated 9
Active, not recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zemplar

Sponsor Name

Sponsor Name for Zemplar
Sponsor Trials
Abbott 36
National Cancer Institute (NCI) 5
AbbVie (prior sponsor, Abbott) 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zemplar
Sponsor Trials
Industry 54
Other 49
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Zemplar (Paricalcitol): Clinical Trials, Market Analysis, and Projections

Introduction to Zemplar (Paricalcitol)

Zemplar, also known as paricalcitol, is a synthetic vitamin D analog used primarily for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis. Here, we will delve into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Efficacy

Approval and Indications

Zemplar is medically necessary for the prevention and treatment of SHPT in CKD patients on hemodialysis, as approved by Aetna and other health organizations. Clinical trials have shown that paricalcitol is effective in reducing intact parathyroid hormone (iPTH) levels, which is a key indicator of SHPT[1].

Trial Outcomes

In various clinical trials, paricalcitol has demonstrated its efficacy in managing SHPT. For instance, when used in conjunction with other treatments, paricalcitol has shown significant reductions in iPTH levels, thereby improving the management of calcium and phosphate levels in CKD patients.

Market Analysis

Current Market Size

The paricalcitol market was valued at USD 1.4 billion in 2023. This market includes various segments such as capsules, injections, oral solutions, and both branded and generic forms of the drug[2].

Growth Projections

The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7% from 2024 to 2031, reaching a projected value of USD 2.4 billion by 2031. This growth is driven by the increasing prevalence of CKD and associated SHPT, as well as the growing adoption of paricalcitol for regulating calcium and phosphate levels in CKD patients[2].

Market Segments

The paricalcitol market is segmented by application, product, and geography. Key segments include:

  • By Application: Capsule, injection, oral solution
  • By Product: Secondary hyperparathyroidism, chronic kidney disease, end-stage renal disease, vitamin D deficiency, bone health
  • By Geography: North America, Europe, APAC, Middle East & Asia, Rest of World[2].

Competitive Landscape

The market is competitive, with key players including AbbVie, Teva Pharmaceuticals, Mylan, Sun Pharmaceutical, and others. These companies are involved in various strategies such as new product launches, collaborations, and expansions to maintain their market share[2].

Market Dynamics

Drivers

The growth of the paricalcitol market is driven by several factors:

  • Increasing Prevalence of CKD: The rising number of patients with CKD and associated SHPT is a significant driver.
  • Growing Geriatric Population: The elderly are more susceptible to CKD, contributing to the market growth.
  • Potential in Vitamin D Deficiency: Paricalcitol’s role in treating vitamin D deficiency also presents growth opportunities[2].

Restraints

Despite the growth potential, there are some restraints to consider:

  • Regulatory Hurdles: Strict regulatory requirements and the need for extensive clinical trials can slow market entry.
  • Competition: The presence of other vitamin D analogs and phosphate binders in the market can pose competition[2].

Porter’s Five Forces Analysis

Buyer’s Bargaining Power

Buyers, including healthcare providers and patients, have moderate bargaining power due to the availability of alternative treatments. However, the specificity of paricalcitol for SHPT management gives it a competitive edge[2].

Supplier’s Bargaining Power

Suppliers, such as API manufacturers like Carbogen Amcis and Formosa Laboratories, have significant bargaining power due to the specialized nature of the product[5].

Threat of New Entrants

The threat of new entrants is moderate due to the high barriers to entry, including regulatory approvals and the need for extensive clinical trials[2].

Threat of Substitutes

The threat of substitutes is high due to the presence of other vitamin D analogs and phosphate binders. However, paricalcitol’s efficacy and safety profile help it maintain market share[2].

Degree of Competition

The degree of competition is high, with multiple players in the market. Companies engage in various strategies to differentiate their products and maintain market share[2].

Regional Analysis

The paricalcitol market is analyzed across various regions, including North America, Europe, APAC, and others. North America is expected to be a significant market due to the high prevalence of CKD and advanced healthcare infrastructure. APAC is also anticipated to grow rapidly due to the increasing healthcare expenditure and growing awareness of CKD management[2].

Key Players and Their Strategies

Key players in the paricalcitol market include:

  • AbbVie: Known for its strong research and development capabilities.
  • Teva Pharmaceuticals: Engaged in various collaborations and product launches.
  • Mylan: Focused on generic and branded versions of paricalcitol.
  • Sun Pharmaceutical: Expanding its presence through strategic acquisitions and partnerships[2].

These companies are involved in continuous innovation, collaborations, and expansions to maintain their competitive edge.

Future Projections

The future of the paricalcitol market looks promising, driven by the increasing demand for effective CKD management. Here are some key projections:

  • Market Size: Expected to reach USD 2.4 billion by 2031.
  • Growth Rate: Anticipated CAGR of 7% from 2024 to 2031.
  • Regional Growth: APAC and North America are expected to be significant growth regions[2].

Conclusion

Zemplar (paricalcitol) is a crucial drug in the management of SHPT in CKD patients. With a strong clinical trial background and growing market demand, the paricalcitol market is poised for significant growth. Understanding the market dynamics, competitive landscape, and regional analysis is essential for stakeholders to make informed decisions.

Key Takeaways

  • Clinical Efficacy: Paricalcitol is effective in reducing iPTH levels and managing SHPT.
  • Market Growth: The market is expected to grow at a CAGR of 7% from 2024 to 2031.
  • Key Drivers: Increasing prevalence of CKD, growing geriatric population, and potential in treating vitamin D deficiency.
  • Competitive Landscape: High competition with key players like AbbVie, Teva Pharmaceuticals, and Mylan.
  • Regional Analysis: North America and APAC are expected to be significant growth regions.

FAQs

What is Zemplar (paricalcitol) used for?

Zemplar (paricalcitol) is used for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis.

What is the current market size of the paricalcitol market?

The paricalcitol market was valued at USD 1.4 billion in 2023.

What is the projected growth rate of the paricalcitol market?

The market is expected to grow at a CAGR of 7% from 2024 to 2031.

Who are the key players in the paricalcitol market?

Key players include AbbVie, Teva Pharmaceuticals, Mylan, Sun Pharmaceutical, and others.

What are the main drivers of the paricalcitol market growth?

The main drivers include the increasing prevalence of CKD, growing geriatric population, and the potential in treating vitamin D deficiency.

Which regions are expected to see significant growth in the paricalcitol market?

North America and APAC are expected to be significant growth regions.

Sources

  1. Aetna: Calcitriol, Etelcalcetide, and Paricalcitol Injections.
  2. Market Research Intellect: Paricalcitol Market Size and Projections.
  3. Biospace: U.S. Clinical Trials Market Size Industry Analysis Report, 2033.
  4. ABPI: Global rankings - Number of industry clinical trials initiated in 2021, by country, by phase.
  5. Valuates Reports: Global Paricalcitol API Market Research Report.
Last updated: 2025-01-03

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.